{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:26Z","timestamp":1790666546880,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sacituzumab govitecan (SG), an antibody\u2013drug conjugate targeting TROP-2, demonstrated superior efficacy over standard chemotherapy in heavily pretreated metastatic triple-negative breast cancer (mTNBC) in the ASCENT trial. However, real-world data remain limited. This study evaluated the effectiveness and safety of SG in an unselected multinational cohort of patients with mTNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included 303 women who initiated SG treatment between August 2021 and April 2025 across 18 oncology centers in Poland, the Czech Republic and Slovakia, within the Central European Breast Cancer Collaboration (CEBCC-102). Primary endpoints were median progression-free survival (mPFS) and overall survival (mOS). Secondary objectives included response pattern, safety and identification of factors influencing outcomes. Adverse events (AEs) were graded using Common Terminology Criteria for AE, version 5.0, and treatment response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up was 8.8\u2009months (IQR 4.5-14.4). The mPFS was 4.4\u2009months, and mOS was 11.3\u2009months. The overall response rate was 30.7%. The most frequent AEs were hematologic: neutropenia (69.0%) and anemia (39.6%). In multivariate Cox analyses, poor ECOG performance status and liver metastases were independently associated with worse outcomes. Diarrhea and hypersensitivity reactions showed favorable prognostic associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this largest real-world cohort, the clinical benefit of SG observed in the ASCENT trial was confirmed under routine practice conditions. Poor performance status and liver metastases predicted inferior outcomes, while certain treatment-related AEs warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag014","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T12:34:12Z","timestamp":1768653252000},"source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5864-0877","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"first","affiliation":[{"name":"Department of Oncology, Wroclaw Medical University , Wroc\u0142aw 50-367,","place":["Poland"]},{"name":"Lower Silesian Comprehensive Cancer Center , Wroc\u0142aw, 53-413","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch , Gliwice 44-102,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"\u017bubrowska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Holy Cross Cancer Center , Kielce 25-734,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Ru\u0161inov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, Stefan Kukura Hospital Michalovce , Michalovce 071 01, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital , Olomouc 779 00,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Konieczna","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology , Warsaw 02-781,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"M\u0142odzi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology , Warsaw 02-781,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Winsko-Szcz\u0119snowicz","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, M. Sklodowska-Curie Bialystok Oncology Center , Bia\u0142ystok 15-027,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[{"name":"Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology , \u0141\u00f3d\u017a 93-513,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"P\u0119kala","sequence":"additional","affiliation":[{"name":"Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology , \u0141\u00f3d\u017a 93-513,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Krej\u010d\u00ed","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Faculty of Medicine, Charles University in Prague and Bulovka University Hospital , Prague 121 08,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0160ustr","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Faculty of Medicine in Pilsen, Charles University and University Hospital Pilsen , Plzen 301 00,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Kol\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University , Hradec Kralove 500 05,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Maritime Hospital in Gdynia , Gdynia 81-519,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szymanik-Resko","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Maritime Hospital in Gdynia , Gdynia 81-519,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Soumarov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady , Prague 128 44,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Ciszewski","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases and Immuno-Oncology, Medical University of Lublin , Lublin 20-400,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Hol\u00e1nek","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University , Brno 656 53,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogumi\u0142a","family":"Czartoryska-Ar\u0142ukowicz","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, M. Sklodowska-Curie Bialystok Oncology Center , Bia\u0142ystok 15-027,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wroclaw Medical University , Wroc\u0142aw 50-367,","place":["Poland"]},{"name":"Lower Silesian Comprehensive Cancer Center , Wroc\u0142aw, 53-413","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Smok-Kalwat","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Holy Cross Cancer Center , Kielce 25-734,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch , Gliwice 44-102,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch , Krakow 31-115,","place":["Poland"]},{"name":"Department of Anatomy, Jagiellonian University Medical College , Krak\u00f3w 31-008,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Malej\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"II Oncology Clinic of LFUK and NO\u00da, National Cancer Institute , Bratislava 833 10, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital , Prague 121 08,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch , Krakow 31-115,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026021523164551600_oyag014-B1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: a review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J"},{"key":"2026021523164551600_oyag014-B2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2026021523164551600_oyag014-B3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"2026021523164551600_oyag014-B4","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026021523164551600_oyag014-B5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021523164551600_oyag014-B6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026021523164551600_oyag014-B7","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021523164551600_oyag014-B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026021523164551600_oyag014-B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188991","volume-title":"Biochimica Et Biophysica Acta\u2014Reviews on Cancer","author":"P\u00fcsk\u00fcll\u00fco\u011flu","year":"2023"},{"key":"2026021523164551600_oyag014-B10","doi-asserted-by":"crossref","first-page":"17588359231200454","DOI":"10.1177\/17588359231200454","article-title":"Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany","volume":"15","author":"Reinisch","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026021523164551600_oyag014-B11","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","article-title":"Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom","volume":"130","author":"Hanna","year":"2024","journal-title":"Br J Cancer"},{"key":"2026021523164551600_oyag014-B12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/OP.24.00242","article-title":"Real-World clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"21","author":"Alaklabi","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026021523164551600_oyag014-B13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases","volume":"31","author":"De Moura","year":"2024","journal-title":"Breast Cancer"},{"key":"2026021523164551600_oyag014-B14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40487-024-00307-1","article-title":"Sacituzumab govitecan for second and subsequent line palliative treatment of patients with triple-negative breast cancer: a polish real-world multicenter cohort study","volume":"12","author":"P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","journal-title":"Oncol Ther"},{"key":"2026021523164551600_oyag014-B15","doi-asserted-by":"crossref","first-page":"1362641","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front Oncol"},{"key":"2026021523164551600_oyag014-B16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13092059","article-title":"Effectiveness and safety of sacituzumab govitecan in real-world clinical practice in patients with metastatic triple-negative and HR+\/HER2-negative breast cancer","volume":"13","author":"Lago-Ballester","year":"2025","journal-title":"Biomedicines"},{"key":"2026021523164551600_oyag014-B17","doi-asserted-by":"crossref","first-page":"17588359251363104","DOI":"10.1177\/17588359251363104","article-title":"Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohort","volume":"17","author":"Pieni\u0105\u017cek","year":"2025","journal-title":"Ther Adv Med Oncol [Internet]"},{"key":"2026021523164551600_oyag014-B18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-025-07825-0","article-title":"Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis","volume":"214","author":"Pieni\u0105\u017cek","year":"2025","journal-title":"Breast Cancer Res Treat [Internet]"},{"key":"2026021523164551600_oyag014-B19","article-title":"S\u00daKL\u2014p\u0159ehled l\u00e9\u010div [Internet]","year":"2025"},{"key":"2026021523164551600_oyag014-B20","article-title":"Ministerstvo zdravotn\u00edctva slovenskej republiky [Internet]","year":"2025"},{"key":"2026021523164551600_oyag014-B21","article-title":"Announcements of the minister of health\u2014list of reimbursed medications [internet]"},{"key":"2026021523164551600_oyag014-B22","article-title":"Cancer institute N. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]","year":"2017"},{"key":"2026021523164551600_oyag014-B23","article-title":"Summary of product characteristics of sacitzumab govitecan [Internet]"},{"key":"2026021523164551600_oyag014-B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026021523164551600_oyag014-B25","article-title":"ESMO Guidance for Reporting Oncology real-World Evidence (ESMO-GROW) | ESMO [Internet]","year":"2025"},{"key":"2026021523164551600_oyag014-B26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2026021523164551600_oyag014-B27","doi-asserted-by":"crossref","first-page":"e70096","DOI":"10.1002\/cam4.70096","article-title":"UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan","volume":"13","author":"Wong","year":"2024","journal-title":"Cancer Med"},{"key":"2026021523164551600_oyag014-B28","doi-asserted-by":"crossref","first-page":"103309","DOI":"10.1016\/j.eclinm.2025.103309","article-title":"Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial","volume":"85","author":"P\u00e9rez-Garc\u00eda","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026021523164551600_oyag014-B29","article-title":"For HCP\u2019s | Trodelvy\u00ae (sacituzumab govitecan-hziy) hypersensitivity and infusion-related reactions [Internet]","year":"2026"},{"key":"2026021523164551600_oyag014-B30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/cpt.3495","article-title":"Exposure\u2013response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic triple-negative breast cancer","volume":"117","author":"Sathe","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026021523164551600_oyag014-B31","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"2026021523164551600_oyag014-B32","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/cpt.1530","article-title":"Population pharmacokinetic modeling and exposure\u2013response assessment for the antibody-drug conjugate brentuximab vedotin in Hodgkin\u2019s lymphoma in the phase III ECHELON-1 study","volume":"106","author":"Suri","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026021523164551600_oyag014-B33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026021523164551600_oyag014-B34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-025-04823-3","article-title":"Sacituzumab govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety","volume":"95","author":"Pieni\u0105\u017cek","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021523164551600_oyag014-B35","doi-asserted-by":"crossref","first-page":"101387","DOI":"10.1016\/j.esmoop.2023.101387","article-title":"198P relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): post hoc analysis from the phase III ASCENT study","volume":"8","author":"de Azambuja","year":"2023","journal-title":"ESMO Open [Internet]"},{"key":"2026021523164551600_oyag014-B36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026021523164551600_oyag014-B37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"2026021523164551600_oyag014-B38","doi-asserted-by":"crossref","first-page":"189369","DOI":"10.1016\/j.bbcan.2025.189369","article-title":"Sequencing of antibody drug conjugates in breast cancer: evidence gap and future directions","volume":"1880","author":"Pacholczak-Madej","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag014\/66560635\/oyag014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag014\/66560635\/oyag014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag014\/66560635\/oyag014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:16:58Z","timestamp":1771215418000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag014\/8439752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag014","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,23]]},"article-number":"oyag014"}}